ABSTRACT

Objective: To determine the risk of breast cancer due to lobular carcinoma in situ (LCIS).

Methods: This retrospective IRB-approved study identifed cases of LCIS after percutaneous breast biopsy from 7/2005 to 7/2022. Excluded were cases with less than 2 years of imaging surveillance or a concurrent ipsilateral breast cancer diagnosis within 6 months of the LCIS diagnosis. Final outcomes of cancer versus no cancer were determined by pathology at surgical excision or the absence of cancer on imaging surveillance.

Results: A total of 116 LCIS lesions were identifed. The primary imaging fndings targeted for percutaneous biopsy include calcifcations (50.0%, 58/116), MR enhancing lesions (25.0%, 29/116), noncalcifed mammographic architectural distortions (10.3%, 12/116), or masses (14.7%, 17/116). Surgical excision was performed in 49.1% (57/116) and imaging surveillance was performed in 50.9% (59/116) of LCIS cases. There were 22 cancers of which 11 cancers were discovered at immediate excision [19.3% (11/57) immediate upgrade] and 11 cancers developed later while on imaging surveillance [18.6% (11/59) delayed risk for cancer]. Among all 22 cancers, 63.6% (14/22) occurred at the site of LCIS (11 at immediate excision and 3 at surveillance) and 36.4% (8/22) occurred at a location away from the site of LCIS (6 in a diferent quadrant and 2 in the contralateral breast).

Conclusion: LCIS has both an immediate risk (19.3%) and a delayed risk (18.6%) for cancer with 90.9% occurring in the ipsilateral breast (63.6% at and 27.3% away from the site of LCIS) and 9.1% occurring in the contralateral breast.

Keywords: Lobular carcinoma in situ, Cancer, Variant, Pleomorphic, Florid